|
DK1545613T3
(da)
|
2002-07-31 |
2011-11-14 |
Seattle Genetics Inc |
Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
|
|
CN107213469A
(zh)
|
2003-11-06 |
2017-09-29 |
西雅图基因公司 |
能够与配体偶联的单甲基缬氨酸化合物
|
|
NZ574215A
(en)
|
2006-07-18 |
2012-07-27 |
Sanofi Aventis |
Antagonist antibody against epha2 for the treatment of cancer
|
|
EP2631248B9
(en)
|
2007-06-15 |
2018-05-23 |
Medigene AG |
Treatment of tumors using specific anti-L1 antibody
|
|
CL2008002083A1
(es)
|
2007-07-16 |
2008-11-21 |
Genentech Inc |
Anticuerpo humanizado anti-cd79b/igbeta/b29; inmunoconjugado; metodo in vitro para determinar presencia de cd79b, inhibir crecimiento de celula con cd79b, o para detectara celula b; metodo para elaborar dicho anticyerpo humanizado; acido nucleico; celula huesped; composicion; metodo de elaboracion de inmunoconjugado; uso medico
|
|
NZ583367A
(en)
|
2007-07-16 |
2012-10-26 |
Genentech Inc |
Anti-cd79b antibodies and immunoconjugates and methods of use
|
|
WO2009028639A1
(ja)
*
|
2007-08-30 |
2009-03-05 |
Daiichi Sankyo Company, Limited |
抗ｅｐｈａ２抗体
|
|
JP2011509079A
(ja)
|
2007-12-24 |
2011-03-24 |
オックスフォード ビオトヘラペウトイクス エルティーディー． |
エフリンａ型受容体１０タンパク質
|
|
ES2643239T3
(es)
|
2008-01-31 |
2017-11-21 |
Genentech, Inc. |
Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso
|
|
US20100009390A1
(en)
*
|
2008-05-09 |
2010-01-14 |
The Regents Of The University Of California |
Mutant antibodies with high affinity for egfr
|
|
US20100008978A1
(en)
*
|
2008-05-09 |
2010-01-14 |
The Regents Of The University Of California |
Nanoparticles effective for internalization into cells
|
|
UY32914A
(es)
|
2009-10-02 |
2011-04-29 |
Sanofi Aventis |
Anticuerpos que se usan específicamente al receptor epha2
|
|
AU2011213609B2
(en)
*
|
2010-02-08 |
2016-11-03 |
Agensys, Inc. |
Antibody drug conjugates (ADC) that bind to 161P2F10B proteins
|
|
KR20130056855A
(ko)
|
2010-03-01 |
2013-05-30 |
카리스 라이프 사이언스 룩셈부르크 홀딩스 |
치료진단용 생물학적 지표들
|
|
KR20130043104A
(ko)
|
2010-04-06 |
2013-04-29 |
카리스 라이프 사이언스 룩셈부르크 홀딩스 |
질병용 순환 생물학적 지표들
|
|
EA201291180A1
(ru)
|
2010-05-06 |
2013-05-30 |
Новартис Аг |
Композиции и способы применения терапевтических антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6)
|
|
KR101834026B1
(ko)
|
2010-06-19 |
2018-03-02 |
메모리얼 슬로안-케터링 캔서 센터 |
항-ｇｄ2 항체
|
|
KR20130048242A
(ko)
*
|
2010-07-22 |
2013-05-09 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
항-종양 항원 항체 및 이용 방법
|
|
PL2606070T3
(pl)
|
2010-08-20 |
2017-06-30 |
Novartis Ag |
Przeciwciała dla receptora epidermalnego czynnika wzrostu 3 (her3)
|
|
US20130245233A1
(en)
|
2010-11-24 |
2013-09-19 |
Ming Lei |
Multispecific Molecules
|
|
MX379481B
(es)
|
2010-12-06 |
2025-03-11 |
Seagen Inc |
Anticuerpos humanizados a liv-1 y uso de los mismos para tratar cancer
|
|
MX356400B
(es)
|
2010-12-08 |
2018-05-28 |
Abbvie Stemcentrx Llc |
Moduladores novedosos y metodos de uso.
|
|
SA112330278B1
(ar)
|
2011-02-18 |
2015-10-09 |
ستيم سينتركس، انك. |
مواد ضابطة جديدة وطرق للاستخدام
|
|
AU2012244673A1
(en)
*
|
2011-04-21 |
2013-11-28 |
Seattle Genetics, Inc. |
Novel binder-drug conjugates (ADCs) and their use
|
|
SMT201900500T1
(it)
*
|
2011-05-08 |
2019-11-13 |
Legochem Biosciences Inc |
Coniugati di agente protettivo-proteina e metodo per preparare i medesimi
|
|
AU2012340766B2
(en)
|
2011-11-23 |
2018-05-10 |
Medimmune, Llc |
Binding molecules specific for HER3 and uses thereof
|
|
US20130273029A1
(en)
|
2011-12-05 |
2013-10-17 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3
|
|
AU2012349735B2
(en)
|
2011-12-05 |
2016-05-19 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (HER3)
|
|
MX2014014894A
(es)
|
2012-06-04 |
2015-02-20 |
Irm Llc |
Metodos de marcado especifico del sitio y moleculas producidas mediante los mismos.
|
|
AU2013289970A1
(en)
*
|
2012-07-13 |
2015-01-22 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for regulating CAR T cells
|
|
CN112587671A
(zh)
|
2012-07-18 |
2021-04-02 |
博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
|
KR101645905B1
(ko)
|
2012-10-12 |
2016-08-04 |
스피로즌 살 |
피롤로벤조디아제핀 및 그의 컨주게이트
|
|
US9353150B2
(en)
|
2012-12-04 |
2016-05-31 |
Massachusetts Institute Of Technology |
Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
|
|
BR112015018899B1
(pt)
|
2013-02-08 |
2023-09-26 |
Novartis Ag |
Imunoconjugados, composição farmacêutica, anticorpos igg modificados ou fragmentos de anticorpo modificados dos mesmos e seu método de produção, e célula hospedeira
|
|
WO2014124258A2
(en)
|
2013-02-08 |
2014-08-14 |
Irm Llc |
Specific sites for modifying antibodies to make immunoconjugates
|
|
EP2968585B1
(en)
|
2013-03-13 |
2018-07-18 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
|
US9498532B2
(en)
|
2013-03-13 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
|
CA2902026C
(en)
*
|
2013-03-13 |
2023-08-29 |
Prothena Biosciences Limited |
Tau immunotherapy
|
|
CN105246916A
(zh)
|
2013-03-14 |
2016-01-13 |
诺华股份有限公司 |
针对notch 3的抗体
|
|
JP6482525B2
(ja)
|
2013-03-15 |
2019-03-13 |
メモリアル スローン ケタリング キャンサー センター |
高親和性抗ｇｄ２抗体
|
|
CN105007950B
(zh)
|
2013-03-15 |
2019-01-15 |
诺华股份有限公司 |
抗体药物缀合物
|
|
US11305012B2
(en)
|
2013-09-24 |
2022-04-19 |
Medimmune, Llc |
Binding molecules specific for HER3 and uses thereof
|
|
WO2015065954A1
(en)
*
|
2013-11-04 |
2015-05-07 |
Pfizer, Inc. |
Anti-efna4 antibody-drug conjugates
|
|
AU2015205753A1
(en)
|
2014-01-10 |
2016-07-21 |
Birdie Biopharmaceuticals Inc. |
Compounds and compositions for treating HER2 positive tumors
|
|
EA201691827A1
(ru)
|
2014-03-12 |
2017-01-30 |
Новартис Аг |
Конкретные участки для модификации антител с целью получения иммуноконъюгатов
|
|
US10745490B2
(en)
|
2014-04-11 |
2020-08-18 |
Celldex Therapeutics, Inc. |
Anti-ErbB antibodies and methods of use thereof
|
|
HRP20210292T1
(hr)
|
2014-04-30 |
2021-04-16 |
Pfizer Inc. |
Anti-ptk7 protutijelo-lijek konjugati
|
|
WO2016004876A1
(en)
|
2014-07-09 |
2016-01-14 |
Shanghai Birdie Biotech, Inc. |
Anti-pd-l1 combinations for treating tumors
|
|
WO2016007741A1
(en)
|
2014-07-11 |
2016-01-14 |
The Regents Of The University Of California |
Tumor selective macropinocytosis-dependent rapidly internalizing antibodies
|
|
WO2016020791A1
(en)
|
2014-08-05 |
2016-02-11 |
Novartis Ag |
Ckit antibody drug conjugates
|
|
EA201790334A1
(ru)
|
2014-08-12 |
2017-06-30 |
Новартис Аг |
Конъюгаты анти-cdh6 антитела с лекарственным средством
|
|
CN112587672A
(zh)
*
|
2014-09-01 |
2021-04-02 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-pd-l1结合物
|
|
WO2016037644A1
(en)
|
2014-09-10 |
2016-03-17 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
|
DK3262071T3
(da)
|
2014-09-23 |
2020-06-15 |
Hoffmann La Roche |
Fremgangsmåde til anvendelse af anti-CD79b-immunkonjugater
|
|
DK3200822T3
(da)
|
2014-09-30 |
2021-07-12 |
Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts |
Bindingsmolekyler, i særdeleshed antistoffer, der binder til l1cam (cd171)
|
|
JP6784668B2
(ja)
|
2014-10-10 |
2020-11-11 |
ファイザー・インク |
相乗的オーリスタチン組合せ
|
|
RS61853B1
(sr)
|
2014-10-29 |
2021-06-30 |
Bicyclerd Ltd |
Biciklični peptidni ligandi specifični za mt1-mmp
|
|
TW201625692A
(zh)
|
2014-11-14 |
2016-07-16 |
諾華公司 |
抗體藥物結合物
|
|
EP3221351B1
(en)
*
|
2014-11-19 |
2024-11-13 |
Memorial Sloan-Kettering Cancer Center |
Methods and compositions for cancer treating conditions relating to over expressions of epha2
|
|
US20190194315A1
(en)
|
2015-06-17 |
2019-06-27 |
Novartis Ag |
Antibody drug conjugates
|
|
CN106943597A
(zh)
|
2016-01-07 |
2017-07-14 |
博笛生物科技（北京）有限公司 |
用于治疗肿瘤的抗-egfr组合
|
|
CN115350279A
(zh)
|
2016-01-07 |
2022-11-18 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-her2组合
|
|
CN115554406A
(zh)
|
2016-01-07 |
2023-01-03 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-cd20组合
|
|
EP3851457A1
(en)
|
2016-01-21 |
2021-07-21 |
Novartis AG |
Multispecific molecules targeting cll-1
|
|
KR20220157515A
(ko)
*
|
2016-03-15 |
2022-11-29 |
씨젠 인크. |
Liv1-adc와 화학요법제를 사용한 병용 요법
|
|
WO2017197045A1
(en)
|
2016-05-11 |
2017-11-16 |
Movassaghi Mohammad |
Convergent and enantioselective total synthesis of communesin analogs
|
|
JP2019534882A
(ja)
|
2016-10-11 |
2019-12-05 |
メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ |
免疫介在性療法薬を有する抗体−薬物コンジュゲート
|
|
KR102617264B1
(ko)
|
2016-10-19 |
2023-12-29 |
인벤라 인코포레이티드 |
항체 구조물
|
|
JP7681879B2
(ja)
|
2016-12-22 |
2025-05-23 |
ウニヴェルシタ・デリ・ストゥディ・マニャ・グレチア・カタンツァーロ |
Ｃｄ４３の固有のシアログリコシル化がん関連エピトープを標的化するモノクローナル抗体
|
|
JOP20190187A1
(ar)
|
2017-02-03 |
2019-08-01 |
Novartis Ag |
مترافقات عقار جسم مضاد لـ ccr7
|
|
WO2018185618A1
(en)
|
2017-04-03 |
2018-10-11 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
|
|
CN118515666A
(zh)
|
2017-04-27 |
2024-08-20 |
博笛生物科技有限公司 |
2-氨基-喹啉衍生物
|
|
US20200179511A1
(en)
|
2017-04-28 |
2020-06-11 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
WO2018209239A1
(en)
|
2017-05-11 |
2018-11-15 |
Massachusetts Institute Of Technology |
Potent agelastatin derivatives as modulators for cancer invasion and metastasis
|
|
KR20200019226A
(ko)
|
2017-06-23 |
2020-02-21 |
버디 바이오파마슈티칼즈, 인크. |
약학 조성물
|
|
EP3645549A1
(en)
|
2017-06-26 |
2020-05-06 |
BicycleRD Limited |
Bicyclic peptide ligands with detectable moieties and uses thereof
|
|
WO2019016772A2
(en)
|
2017-07-21 |
2019-01-24 |
Novartis Ag |
COMPOSITIONS AND METHODS FOR TREATING CANCER
|
|
JP7670481B2
(ja)
|
2017-08-04 |
2025-04-30 |
バイスクルテクス・リミテッド |
Ｃｄ１３７に対して特異的な二環式ペプチドリガンド
|
|
US11525002B2
(en)
|
2017-10-11 |
2022-12-13 |
Board Of Regents, The University Of Texas System |
Human PD-L1 antibodies and methods of use therefor
|
|
US10640508B2
(en)
|
2017-10-13 |
2020-05-05 |
Massachusetts Institute Of Technology |
Diazene directed modular synthesis of compounds with quaternary carbon centers
|
|
CN110914304B
(zh)
*
|
2017-11-10 |
2022-07-26 |
江苏恒瑞医药股份有限公司 |
Cd96抗体、其抗原结合片段及医药用途
|
|
KR20200128518A
(ko)
|
2018-02-23 |
2020-11-13 |
바이사이클티엑스 리미티드 |
다량체성 비사이클릭 펩타이드 리간드
|
|
EP3768726B1
(en)
|
2018-03-23 |
2024-10-30 |
Board of Regents, The University of Texas System |
Dual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor
|
|
JP7514765B2
(ja)
|
2018-03-23 |
2024-07-11 |
ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム |
ヒトｐｄ－ｌ１およびｐｄ－ｌ２に対する二重特異性抗体およびその使用方法
|
|
JP7390301B2
(ja)
|
2018-03-23 |
2023-12-01 |
ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム |
ヒトｐｄ－ｌ２抗体およびその使用方法
|
|
JP2021524449A
(ja)
|
2018-05-23 |
2021-09-13 |
アーデーセー セラピューティクス ソシエテ アノニム |
分子アジュバント
|
|
WO2019232449A1
(en)
|
2018-06-01 |
2019-12-05 |
Eisai R&D Management Co., Ltd. |
Splicing modulator antibody-drug conjugates and methods of use
|
|
CA3102349A1
(en)
|
2018-06-05 |
2019-12-12 |
King's College London |
Btnl3/8 targeting constructs for delivery of payloads to the gastrointestinal system
|
|
CN112566671A
(zh)
*
|
2018-06-07 |
2021-03-26 |
美真达治疗公司 |
使用抗体药物缀合物(adc)的治疗方法
|
|
US11180531B2
(en)
|
2018-06-22 |
2021-11-23 |
Bicycletx Limited |
Bicyclic peptide ligands specific for Nectin-4
|
|
GB201810316D0
(en)
*
|
2018-06-22 |
2018-08-08 |
Bicyclerd Ltd |
Peptide ligands for binding to EphA2
|
|
CN113329769A
(zh)
|
2018-10-11 |
2021-08-31 |
斯克里普斯研究学院 |
具有反应性精氨酸的抗体化合物及相关的抗体药物缀合物
|
|
US20230053449A1
(en)
|
2018-10-31 |
2023-02-23 |
Novartis Ag |
Dc-sign antibody drug conjugates
|
|
GB201820325D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for psma
|
|
GB201820288D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicycle Tx Ltd |
Bicycle peptide ligaands specific for MT1-MMP
|
|
BR112021010936A2
(pt)
|
2018-12-13 |
2021-08-31 |
Eisai R&D Management Co., Ltd. |
Conjugados anticorpo-fármaco de herboxidieno e métodos de uso
|
|
GB201820295D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for MT1-MMP
|
|
CN113474045A
(zh)
|
2018-12-21 |
2021-10-01 |
拜斯科技术开发有限公司 |
Pd-l1特异性的双环肽配体
|
|
WO2020128527A1
(en)
|
2018-12-21 |
2020-06-25 |
Bicyclerd Limited |
Bicyclic peptide ligands specific for pd-l1
|
|
KR20240052881A
(ko)
|
2018-12-21 |
2024-04-23 |
노파르티스 아게 |
Pmel17에 대한 항체 및 이의 접합체
|
|
GB201900529D0
(en)
|
2019-01-15 |
2019-03-06 |
Bicycletx Ltd |
Bicyclic peptide ligands specific for CD38
|
|
WO2020247054A1
(en)
|
2019-06-05 |
2020-12-10 |
Massachusetts Institute Of Technology |
Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
|
|
TWI862640B
(zh)
|
2019-07-30 |
2024-11-21 |
英商拜西可泰克斯有限公司 |
異質雙環肽複合物
|
|
US20230181756A1
(en)
|
2020-04-30 |
2023-06-15 |
Novartis Ag |
Ccr7 antibody drug conjugates for treating cancer
|
|
KR20230074119A
(ko)
|
2020-08-03 |
2023-05-26 |
바이사이클티엑스 리미티드 |
펩타이드 기반 링커
|
|
EP3970752A1
(en)
|
2020-09-17 |
2022-03-23 |
Merck Patent GmbH |
Molecules with solubility tag and related methods
|
|
US20230372528A1
(en)
|
2020-10-16 |
2023-11-23 |
University Of Georgia Research Foundation, Inc. |
Glycoconjugates
|
|
CR20230283A
(es)
|
2020-11-24 |
2023-07-27 |
Novartis Ag |
Anticuerpos anti-cd48, conjugados de anticuerpo-fármaco, y usos de los mismos
|
|
GB202102396D0
(en)
|
2021-02-19 |
2021-04-07 |
Adc Therapeutics Sa |
Molecular adjuvant
|
|
WO2022182415A1
(en)
|
2021-02-24 |
2022-09-01 |
Massachusetts Institute Of Technology |
Himastatin derivatives, and processes of preparation thereof, and uses thereof
|
|
US12162945B2
(en)
|
2021-03-05 |
2024-12-10 |
Immunome, Inc. |
EPHA2 antibodies
|
|
CA3216880A1
(en)
|
2021-04-16 |
2022-10-20 |
Novartis Ag |
Antibody drug conjugates and methods for making thereof
|
|
KR20230060546A
(ko)
|
2021-10-22 |
2023-05-04 |
상트네어바이오사이언스 주식회사 |
두개의 Fc 도메인을 포함하는 항원 결합 단백질 및 이의 용도
|
|
WO2022078524A2
(en)
|
2021-11-03 |
2022-04-21 |
Hangzhou Dac Biotech Co., Ltd. |
Specific conjugation of an antibody
|
|
CA3251592A1
(en)
|
2022-02-17 |
2025-07-09 |
Novelty Nobility Inc. |
ANTIBODY-DRUG CONJUGATE
|
|
US20250387504A1
(en)
|
2022-05-20 |
2025-12-25 |
Novartis Ag |
Antibody-drug conjugates of antineoplastic compounds and methods of use thereof
|
|
WO2023225320A1
(en)
|
2022-05-20 |
2023-11-23 |
Novartis Ag |
Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
|
|
EP4676540A1
(en)
|
2023-03-10 |
2026-01-14 |
Novartis AG |
Panras inhibitor antibody-drug conjugates and methods of use thereof
|
|
TW202504932A
(zh)
|
2023-04-21 |
2025-02-01 |
南韓商百歲生命科學股份有限公司 |
包含兩個ｆｃ區域之抗原結合蛋白及其用途
|